Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: differences between oxaliplatin-naive versus oxaliplatin-pretreated patients
Oxaliplatin use as an intra-arterial hepatic infusion is feasible and efficient after previous systemic oxaliplatin; it showed significant response rates without increased toxicities. It can provide alternative treatments and spare late-setting drugs such as regorafenib and tipiracil-trifluridine for a further palliative intent treatment.
Authors
- Thierry de Baère (ORCID: https://orcid.org/0000-0002-4556-7663)
- David Malka (ORCID: https://orcid.org/0000-0002-7664-0130)
- E Rawadi (ORCID: https://orcid.org/0000-0002-9193-986X)
- C. Smolenschi
- Luisa Pierotti
- Maximiliano Gelli (ORCID: https://orcid.org/0000-0001-9807-4021)
- Marine Valéry (ORCID: https://orcid.org/0000-0002-7787-6911)
- Alina Fuerea (ORCID: https://orcid.org/0009-0002-7074-0189)
- Lambros Tselikas (ORCID: https://orcid.org/0000-0002-8878-4916)
- Baptiste Bonnet (ORCID: https://orcid.org/0000-0002-1061-321X)
- T. Pudlarz (ORCID: https://orcid.org/0009-0006-6591-2213)
- Alice Boilève (ORCID: https://orcid.org/0000-0003-3708-4909)
- Michel Ducreux (ORCID: https://orcid.org/0000-0001-8649-7449)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
- Elena Fernandez-De-Sevilla
- A. Tarabay (ORCID: https://orcid.org/0000-0002-3804-3554)
- V. Boige
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Institute Mutualiste Montsouris (FR)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100173
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00